OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

www.myan.de/article119916.html

Friday news about OXB:

http://www.pharmalive.com/News/index.cfm?articleid=245336&categoryid=40


http://news.scotsman.com/latest.cfm?id=4642498


http://www.biomedicalproducts.com/ShowPR~PUBCODE~090~ACCT~9000000100~ISSUE~0506~RELTYPE~RLSN~PRODCODE~00000000~PRODLETT~C.html


http://www.thisismoney.co.uk/investing-and-markets/article.html?in_article_id=401067&in_page_id=3


http://southflorida.bizjournals.com/southflorida/stories/2005/05/30/daily45.html


http://abcnews.go.com/Health/wireStory?id=816471

Courtesy of qpr (ADV)
Saturday:
From todays Times :
Positive data on the use of Innurex, its gene-based therapy for nerve regeneration, on spinal cord injury helped Oxford Biomedica up 2p to 31p


From todays Financial Times :
Oxford BioMedica rose 8.7 per cent to 31p as the gene therapy company presented encouraging data on its product for nerve repair in spinal cord injuries to the American Society of Gene Therapy meeting in St Louis, Missouri. There was also talk it could announce a licencing deal with Pfizer, the worlds largest pharmaceutical group, for another of its products next week.

From todays Independent :
Oxford BioMedica rose 2.5p to 31.25p on the back of positive trial results from one of its technologies. The stock was also boosted by suggestions the company is on the way to securing a licensing agreement for one of its products with a US pharmaceuticals giant.

On the basis of those reports - me thinks I will start taking the Independent

Nicked from other BBs!

http://www.medicalnewstoday.com/medicalnews.php?newsid=25623

http://maconareaonline.com/news.asp?id=11006

http://news.bbc.co.uk/1/hi/scotland/4607653.stm

http://www.axcessnews.com/health_060405b.shtml

Fin. Mail: "Pfizer deal poised to lift Biomedica shares"

From yesterdays FT.
Oxford BioMedica rose 8.7 per cent to 31p as the gene therapy company presented encouraging data on its product for nerve repair in spinal cord injuries to the American Society of Gene Therapy meeting in St Louis, Missouri. There was also talk it could announce a licencing deal with Pfizer, the world's largest pharmaceutical group, for another of its products next week.

RNS Number:1523N Oxford Biomedica PLC 06 June 2005


FOR IMMEDIATE RELEASE 6 JUNE 2005



OXFORD BIOMEDICA SIGNS LENTIVECTOR(R) LICENSING AGREEMENT WITH PFIZER


Oxford, UK: 6 June 2005 - Oxford BioMedica (LSE: OXB), the leading gene therapy company, announced today that it has signed a licence agreement for its LentiVector technology with Pfizer (NYSE: PFE). The agreement provides Pfizer with use of the Company's proprietary LentiVector gene delivery system for research activities. Under the terms of the agreement, Oxford BioMedica will receive an upfront licence payment and an annual maintenance fee. Further financial details were not disclosed.

Oxford BioMedica's lentivirus-based gene delivery technology, known as LentiVector, is one of the most powerful technologies for the delivery of genes to a wide range of cell and tissue types. The LentiVector technology has applications both in therapeutic products and as a drug discovery tool for target validation and the creation of targeted disease models. It has also been shown to enhance the efficiency of making transgenic birds and mammals. Oxford BioMedica has a comprehensive portfolio of US and European patents that cover the LentiVector technology.

Commenting on the news Oxford BioMedica's Senior Vice President Commercial Development, Peter Nolan, said: "We are delighted to add Pfizer to our list of licensees for the LentiVector technology The versatility and safety of lentiviral vectors make them the system of choice for gene target validation in the drug discovery process as well as for the direct therapeutic applications in neurotherapy that Oxford BioMedica is pursuing. An increasing number of companies are using the LentiVector technology and we expect to establish a number of new partnerships around the technology".


Ends-

Coutesy of Gerry on Adv.

Links to today's News :-

http://biz.yahoo.com/iw/050606/088126.html

http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=490112

http://www.marketwire.com/mw/release_html_b1?release_id=88126

Seems like there's a lot of good-news momentum gathering behind OXB now.

im abit surprised that the sp hasnt gone higher with this rns.

Any thoughts why this has not happened??????

Accord - presumably it is "just another licence" for Lentivector. Numis continues with its sell rating, arguing that commercialisation of any product emanating from use of Lentivector is a long way off. That seems rather strange considering OXB will gain some cash from the deal NOW. Anyway, I am still waiting for a further RNS re Trovax. If the right deal is struck then the shares should test 40p at the very least.

06/06/05 15:00 Director Shareholding RNS

Thanks apple didn`t occur to me to expect another RNS. What do we make of the timing. Can it be tax reasons

Yep, that's what it says in the RNS

Plus the fact that the options were due to expire in 3 months time.

guys and dolls

Due to house move and raising capital i have sold my shares in OXB @ 32p each.

Its been an interesting journey and wish you all well for the future. Who knows I may dip in again if and when I have some free cash.

Ta ta

Keep the faith boys

good rise today and chart looks good too. newsflow to follow and a rerating to take place in the next 18 months or so.

Agree, good day for OXB today and a new high for the year :-)

Big US buying today - I don't think they will be selling soon. Bodes well for the near future.

looking good again.

Up about 20% since the last buying opportunity on 1st June.

Very satisfying but it must be due for some consolidation soon.